Metabolic effects of Troglitazone in patients with diet-controlled type 2 diabetes.

@article{Robinson2004MetabolicEO,
  title={Metabolic effects of Troglitazone in patients with diet-controlled type 2 diabetes.},
  author={Adam C J Robinson and James A R Jeffs and Robert G Gray and P A Bannister and Hugh M Mather and James J. Gallagher and Stephen Robinson and Malcom Nattrass and Soundararajan Venkatesan and David F. Halliday and Desmond Johnston},
  journal={European journal of clinical investigation},
  year={2004},
  volume={34 1},
  pages={29-36}
}
BACKGROUND In order to study the mechanisms of action of Troglitazone (TGZ) in vivo in Type 2 diabetes, its effects were studied on glucose metabolism, lipolysis and very low-density lipoprotein (VLDL) apolipoprotein B100 (apoB) kinetics. MATERIALS AND METHODS A placebo-controlled, double-blind study was performed in 24 diet-treated patients randomized to receive TGZ 600 mg day(-1), TGZ 200 mg day(-1) or placebo for 8 weeks. Glucose and glycerol turnover were assessed after an overnight fast… CONTINUE READING
2 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.

Similar Papers

Loading similar papers…